Telecoms Today
SEE OTHER BRANDS

Catch up with telecommunications news from the world

Telecoms Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Telecoms Today.

Press releases published on May 19, 2025

STMicroelectronics Announces Status of Common Share Repurchase Program

STMicroelectronics Announces Status of Common Share Repurchase Program

STMicroelectronics Announces Status of Common Share Repurchase Program Disclosure of Transactions in Own Shares – Period from May 12, 2025 to May 16, 2025 AMSTERDAM – May 19, 2025 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global …

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the …

TORRAS Redefines the iPhone Case Market with Ostand, OAir, and OFitness Series — A Fusion of Design, Durability, and Intelligent Functionality

TORRAS Redefines the iPhone Case Market with Ostand, OAir, and OFitness Series — A Fusion of Design, Durability, and Intelligent Functionality

LOS ANGELES, May 19, 2025 (GLOBE NEWSWIRE) -- TORRAS, a global leader in premium mobile accessories, is once again setting new industry benchmarks with its latest iPhone case lineup, blending aesthetic elegance, user-first innovation, and intelligent …

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

--Efficacy comparable to anti-IL4/IL13 antibody control --Achieved dose-dependent and durable target modulation in vivo without requiring degradation of STAT6 protein --Avoided broad JAK-mediated immune suppression --Data presented at the American Thoracic …

Vaidio Showcases 9th Generation Vision AI Platform at COMPUTEX 2025

Vaidio Showcases 9th Generation Vision AI Platform at COMPUTEX 2025

TAIPEI, Taiwan, May 19, 2025 (GLOBE NEWSWIRE) -- Vision AI leader Vaidio® announced today it will showcase the 9th generation of its widely-adopted AI Vision Platform at COMPUTEX 2025, taking place at the Taipei Nangang Exhibition Center from May 20 to May …

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its …

Prebid.org Announces Prebid Mobile 3.0.0 – A Major Leap Forward In Making Mobile and In-App Inventory Biddable

Prebid.org Announces Prebid Mobile 3.0.0 – A Major Leap Forward In Making Mobile and In-App Inventory Biddable

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Prebid.org, the organization that oversees open source Prebid programmatic advertising solutions, recently announced the release of Prebid SDK 3.0.0, a major milestone for the open-source in-app bidding solution. …

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, …

Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress

Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress

Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapy BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on …

Alignment Health Plan Recognized as One of Two Medicare Advantage Prescription Drug Plans in the U.S. for Excellence in Pharmacy Quality

Alignment Health Plan Recognized as One of Two Medicare Advantage Prescription Drug Plans in the U.S. for Excellence in Pharmacy Quality

ORANGE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) has been recognized for excellence in quality for its Medicare Advantage prescription drug (MAPD) plan by the Pharmacy Quality Alliance (PQA). The PQA has measured …

Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference

Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference

WARRINGTON, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …

Eascra Biotech Awarded $100,000 MassVentures START Grant

Eascra Biotech Awarded $100,000 MassVentures START Grant

BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Eascra Biotech, a nanomedicine startup, has been awarded a $100,000 Stage I SBIR Targeted Technologies (START) grant funded by the Commonwealth and managed by MassVentures. The funding is to support their work on …

Respira Therapeutics Announces Late-breaking Presentation of RT234 Phase 2b PAH Clinical Trial Results at the American Thoracic Society (ATS) 2025 International Conference

Respira Therapeutics Announces Late-breaking Presentation of RT234 Phase 2b PAH Clinical Trial Results at the American Thoracic Society (ATS) 2025 International Conference

PALO ALTO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Respira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing RT234 (vardenafil inhalation powder) as the first therapy that pulmonary arterial hypertension (PAH) patients …

Rani Therapeutics Announces Research Agreement with Chugai

Rani Therapeutics Announces Research Agreement with Chugai

- Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “ …

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination …

Circuits Integrated Hellas Launches Game-Changing Kythrion Satcom Chipset

Circuits Integrated Hellas Launches Game-Changing Kythrion Satcom Chipset

ATHENS, Greece, May 19, 2025 (GLOBE NEWSWIRE) -- Circuits Integrated Hellas (CIH), a pioneering innovator in advanced satellite communication (Satcom) technology, today launched Kythrion™, its revolutionary chipset platform engineered to transform the …

Reflect Scientific Strengthens Position in Booming AI Data Center Cooling Market with Patented Cryogenic Innovations

Reflect Scientific Strengthens Position in Booming AI Data Center Cooling Market with Patented Cryogenic Innovations

OREM, Utah, May 19, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a pioneer in cryogenic cooling technologies, today highlighted how its patented solutions are uniquely positioned to address the surging global demand for advanced data …

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod …

Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders

Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that …

STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases

STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases

HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces that the American Medical Association …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service